Literature DB >> 29071482

[Nontuberculous mycobacterial infections].

A Nowag1,2, M Platten3,4, G Plum2, P Hartmann5,6,7.   

Abstract

Nontuberculous mycobacterial (NTM) are found ubiquitously in the environment and are usually of low pathogenicity. Infection occurs via inhalation of aerosols, and some species may cause severe infections. The incidence of NTM infections is rising worldwide. The risk of developing NTM disease depends on the susceptibility of the host as well as the frequency and duration of exposure. In addition to congenital immune deficiencies and immunosuppressive therapy, structural lung and systemic diseases, including rheumatoid arthritis (RA), are associated with an increased risk for NTM infections. The immune response to NTM is complex and relies on the interplay between professional phagocytes and lymphoid cells. This interplay is concerted by three key cytokines: interleukin-12 (IL-12), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ). Targeted immunotherapies, e. g., treatment with TNF inhibitors, interfere with these essential pathways and increase the risk of NTM infection significantly. This review focuses on the relationship between the immune response to NTM and intrinsic and iatrogenic dispositions for NTM infection, with an emphasis on RA.

Entities:  

Keywords:  Immunotherapy; Interferon-γ; Interleukin-12; Rheumatoid arthritis; Tumor necrosis factor-α

Mesh:

Substances:

Year:  2017        PMID: 29071482     DOI: 10.1007/s00393-017-0392-3

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  48 in total

1.  Anti-CD20 (rituximab) therapy for anti-IFN-γ autoantibody-associated nontuberculous mycobacterial infection.

Authors:  Sarah K Browne; Rifat Zaman; Elizabeth P Sampaio; Kamonwan Jutivorakool; Lindsey B Rosen; Li Ding; Minjal J Pancholi; Lauren M Yang; Debra Long Priel; Gulbu Uzel; Alexandra F Freeman; Carlton E Hayes; Roger Baxter; Stuart H Cohen; Steven M Holland
Journal:  Blood       Date:  2012-03-08       Impact factor: 22.113

Review 2.  Mycobacterium avium complex infection in the acquired immunodeficiency syndrome.

Authors:  C R Horsburgh
Journal:  N Engl J Med       Date:  1991-05-09       Impact factor: 91.245

3.  A case of latent tuberculosis reactivation in a patient treated with ustekinumab without concomitant isoniazid chemoprophylaxis in the PEARL trial.

Authors:  T-F Tsai; H-Y Chiu; M Song; D Chan
Journal:  Br J Dermatol       Date:  2012-09-27       Impact factor: 9.302

4.  Risk of mycobacterial infections associated with rheumatoid arthritis in Ontario, Canada.

Authors:  Sarah K Brode; Frances B Jamieson; Ryan Ng; Michael A Campitelli; Jeffrey C Kwong; J Michael Paterson; Ping Li; Alexandre Marchand-Austin; Claire Bombardier; Theodore K Marras
Journal:  Chest       Date:  2014-09       Impact factor: 9.410

5.  Mycobacterial infections following bone marrow transplantation: a 20 year retrospective review.

Authors:  V Roy; D Weisdorf
Journal:  Bone Marrow Transplant       Date:  1997-03       Impact factor: 5.483

6.  Mycobacterial infections after kidney transplant.

Authors:  T Jie; A J Matas; K J Gillingham; D E R Sutherland; D L Dunn; A Humar
Journal:  Transplant Proc       Date:  2005-03       Impact factor: 1.066

Review 7.  Leptin in the interplay of inflammation, metabolism and immune system disorders.

Authors:  Vanessa Abella; Morena Scotece; Javier Conde; Jesús Pino; Miguel Angel Gonzalez-Gay; Juan J Gómez-Reino; Antonio Mera; Francisca Lago; Rodolfo Gómez; Oreste Gualillo
Journal:  Nat Rev Rheumatol       Date:  2017-01-05       Impact factor: 20.543

Review 8.  Infections caused by non-tuberculous mycobacteria in recipients of hematopoietic stem cell transplantation.

Authors:  Khalid Ahmed Al-Anazi; Asma M Al-Jasser; Waleed Khalid Al-Anazi
Journal:  Front Oncol       Date:  2014-11-10       Impact factor: 6.244

9.  Risk Factors and Outcomes of Nontuberculous Mycobacterial Disease among Rheumatoid Arthritis Patients: A Case-Control study in a TB Endemic Area.

Authors:  Tsai-Ling Liao; Chin-Fu Lin; Yi-Ming Chen; Hung-Jen Liu; Der-Yuan Chen
Journal:  Sci Rep       Date:  2016-07-11       Impact factor: 4.379

Review 10.  Managing pulmonary nontuberculous mycobacterial infection. time for a patient-centered approach.

Authors:  Giovanni Satta; Timothy Daniel McHugh; James Mountford; Ibrahim Abubakar; Marc Lipman
Journal:  Ann Am Thorac Soc       Date:  2014-01
View more
  2 in total

1.  Mycobacterium intracellulare-Related Immune Reconstitution Syndrome in an HIV Patient: A Case Report.

Authors:  Sebastian Quintero Montealegre; Natalia Medina Jimenez; Diego Molina Castro
Journal:  Cureus       Date:  2022-03-09

2.  MiR-144-3p is associated with pathological inflammation in patients infected with Mycobacteroides abscessus.

Authors:  Hyeon Ji Kim; In Soo Kim; Sung-Gwon Lee; Young Jae Kim; Prashanta Silwal; Ji Young Kim; Jin Kyung Kim; Wonhyoung Seo; Chaeuk Chung; Hyun Kyu Cho; Hee Jae Huh; Seung Cheol Shim; Chungoo Park; Byung Woo Jhun; Eun-Kyeong Jo
Journal:  Exp Mol Med       Date:  2021-01-20       Impact factor: 8.718

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.